top of page
Browse by category
Search

Obesity influences brain morphology and cognitive health
Professor Anqi Qiu, Professor of the Department of Health Technology and Informatics at the Hong Kong Polytechnic University (PolyU) and...

Closure of defects may be more effective for preventing internal hernia post-RYGB
A Cochrane systematic review has concluded that the closure of defects may be more effective than the non‐closure of defects for...

Journal Watch 9/4/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in patients with acquired hypothalamic obesity
Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a...

Medicare and Medicaid will not expand coverage to anti-obesity medications
The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal to expand...


Confronting obesity on World Health Day: A call for a new standard of care
This World Health Day, it is time to confront obesity. Despite advances in obesity treatments, the obesity epidemic continues to...


International Diabetes Federation reports 250 million people are unaware they have diabetes
Nearly one in nine adults (589 million) are now living with diabetes with an estimated 252 million unaware they have the condition,...

Tehran Obesity Treatment Study identifies significant predictors of insufficient weight loss post-BMS
Researchers from Iran, reporting the latest outcomes from the Tehran Obesity Treatment Study, have reported older age, a higher baseline...


Where people shop for their food and the risk of obesity-related cancers
A team of researchers at the University of Connecticut have developed a novel tool to help understand consumer behaviour at the county...

Antag begins trial of AT-7687, a GIPR antagonist designed to address key gaps in obesity treatment
Antag Therapeutics has initiated its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent...
Browse by tag






bottom of page